Question 1

What is QUIZARTINIB used for?

Accepted Answer

QUIZARTINIB (brand name VANFLYTA) is a Other indicated for 1 INDICATIONS AND USAGE VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, and as maintenance monotherapy following consolidation chemotherapy.

Question 2

How does QUIZARTINIB work?

Accepted Answer

QUIZARTINIB works through the following mechanism: 12.1 Mechanism of Action Quizartinib is a small molecule inhibitor of the receptor tyrosine kinase FLT3. Quizartinib and its major active metabolite AC886 bind to the adenosine triphosphate (ATP) binding domain of FLT3 with comparable affinity, and both had 10-fold lower affinity towards FLT3-ITD mutation compared to FLT3 in a binding assay. Quizartinib and AC886 inhibited FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. Quizartinib showed antitumor activity in a mouse model of FLT3-ITD-dependent leukemia..

Question 3

What are the most common side effects of QUIZARTINIB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for QUIZARTINIB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is QUIZARTINIB the same as VANFLYTA?

Accepted Answer

VANFLYTA is a brand name for QUIZARTINIB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

QUIZARTINIB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations